|
TOP NEWS
ENFORCEMENT
THIRD CIRCUIT
EXPERT ANALYSIS
Upshot Of 'Skinny Label' Case May Go Beyond Pharma
The U.S. Supreme Court's pending review of Hikma v. Amarin, over a drugmaker's "skinny label," carries implications for both generics and brand-name pharmaceutical manufacturers, and could shed light on how inducement doctrine should operate in other regulated industries where products have substantial lawful uses, says Jason Shull at Banner Witcoff.
Read full article »
| Save to favorites »
LEGAL INDUSTRY
|